Recro Pharma Inc. competitors

Mr Butler joined Akebia as President and CEO in September, 2013. He has more than 25 years of experience leading the development, launch and commercialization of innovative therapies. He served as CEO of Inspiration Biopharmaceuticals, a company focused on developing products for patients with hemophilia, from 2011 until 2013. He led the sale of the company’s assets, including the company’s lead asset to Baxter Corporation, the world leader in hemophilia. The value of the transactions should total over $1 billion to Inspiration’s shareholders. From 1997 to 2011, Mr Butler held various positions at Genzyme Corporation, one of the world’s largest biotechnology companies. While at Genzyme, he most recently served as President of the company’s rare genetic diseases business, which has developed and commercialized first-to-market, transformative therapies for small patient populations. Mr Butler also led the company’s renal, endocrinology, and cardiovascular businesses, growing the division to $1 billion in revenue. Earlier in his career, he held sales and marketing positions at Amgen and Hoffmann-La Roche. He has spent over twenty years working to improve the lives of patients with kidney disease. He served in a number of commercial roles while at Amgen for Epogen® and he led the renal business at Genzyme which brought Renagel®, Renvela®, and Hectorol® to these patients. He currently serves as the chairman of the American Kidney Fund board of trustees. The AKF is the leading patient focused charitable organization in kidney disease, providing assistance to one in 5 patients on kidney dialysis in the US. Mr Butler received his BA degree in Chemistry from Manhattan College and his MBA degree from Baruch College.

Mike Raab has been Chief Executive Officer and Chairman of Ardelyx since March 2009. Before Ardelyx, Mike was a partner at New Enterprise Associates (NEA) one of the world’s largest and most successful venture capital firms and specialized in healthcare investments focusing on the biotechnology and pharmaceutical sectors. Prior to joining NEA in 2002, Mike spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He was Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation. He built the Latin American division for Genzyme and was also Senior Product Manager for Genzyme’s $1+ billion therapies for Gaucher Disease, Ceredase and Cerezyme, and was instrumental in the worldwide launch of both products. Mike also spent two years with Genzyme’s Diagnostic products and services division. Previous to Genzyme, Mike held business development and sales and marketing positions at Repligen and Bristol-Myers. Mike received his B.A. from DePauw University.

Mr. Sherman joined Chimerix in 2019 as Chief Executive Officer. Before joining the Company, he served as Chief Executive Officer of Endocyte and led it from a $200 million market capitalization to its $2.1 billion acquisition by Novartis in 2018. Mr. Sherman repositioned the company by re-prioritizing the pipeline, acquiring an external asset, and aggressively executing a phase 3 regulatory and clinical strategy. He joined the company in 2006 and as Chief Financial Officer and Chief Operating Officer and was instrumental in Endocyte’s IPO and four subsequent financings. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, graduating as a Tuck Scholar. Mr. Sherman currently serves on the Board of Biospecifics Technologies, Inc, and as Chairman of the Board of Trustees for the Children’s Museum of Indianapolis. He also served on the Board of Directors at Mead Johnson Nutrition until the company’s acquisition by Reckitt Benckiser.

Mr. George B. Kauffman is a Chairman Chief Executive Officer;Chief Investment Officier at RIGEL PHARMACEUTICALS INC and is based in United States.

As President and Chief Executive Officer of Seres Therapeutics, I’m focused on leading Seres with the belief that microbiome therapies can transform how disease is treated for individuals managing and living with serious disease. Through the combination of proprietary science, innovative technology and rigorous analysis, we’re striving to create a future that includes a revolutionary way of providing new treatment options to healthcare providers so patients can thrive from the inside out.My more than 20 years of experience working in executive leadership roles in biotechnology finance, corporate development and capital markets, drives me to help ensure Seres’ continued growth within the microbiome industry. Our steadfast commitment-from scientific discovery to fulfilling the promise of recovery-aims to help people live more fulfilling lives.

Jason Meyenburg is Chief Executive Officer at Gemini Therapeutics. He has more than 20 years of experience in developing and commercializing therapies for patients with serious conditions. Prior to joining Gemini, Jason served as Chief Commercial Officer at Orchard Therapeutics, a company advancing gene therapies for rare diseases, where he was responsible for building out the global commercial operations. During his tenure at Orchard, the company acquired and integrated the gene therapy portfolio from GSK and launched an IPO of $200 million in 2019. Before Orchard, Jason was Chief Commercial Officer of Vtesse Pharmaceuticals, a company developing a therapy for the rare disease Niemann-Pick C in collaboration with the NIH, and of Sucampo Pharmaceuticals through the acquisition of Vtesse. Before Vtesse and Sucampo, Jason spent 13 years at Alexion Pharmaceuticals in roles of increasing responsibility, including Executive Director Project Management & Japan Operations, Vice President Commercial Operations Northern/Eastern Europe and Middle East/Africa based in Switzerland, and Senior Vice President, Commercial Operations, The Americas. Jason holds an MBA from Duke University and a B.S. in biochemistry from University of Maryland, College Park.